Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Blood (2012) 120 (2): 249–258.

https://doi.org/10.1182/blood-2012-02-408492

Published: 2012

Includes: Supplemental data

Journal Articles

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

Blood (2012) 119 (10): 2314–2324.

https://doi.org/10.1182/blood-2011-10-386235

Published: 2012

Includes: Supplemental data

Journal Articles

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Blood (2011) 118 (26): 6920–6929.

https://doi.org/10.1182/blood-2011-08-368225

Published: 2011

Includes: Supplemental data

Journal Articles

MiR-3151 , a Novel MicroRNA Embedded in BAALC , Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Blood (2011) 118 (21): 1462.

https://doi.org/10.1182/blood.V118.21.1462.1462

Published: 2011

Journal Articles

Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia

Blood (2011) 118 (21): 236.

https://doi.org/10.1182/blood.V118.21.236.236

Published: 2011

Journal Articles

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

Blood (2011) 118 (21): 3454.

https://doi.org/10.1182/blood.V118.21.3454.3454

Published: 2011

Journal Articles

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Blood (2011) 118 (21): 417.

https://doi.org/10.1182/blood.V118.21.417.417

Published: 2011

Journal Articles

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield

Blood (2011) 118 (15): 4188–4198.

https://doi.org/10.1182/blood-2011-06-357764

Published: 2011

Includes: Supplemental data

Journal Articles

The prognostic and functional role of microRNAs in acute myeloid leukemia

Guido Marcucci, Krzysztof Mrózek, Michael D. Radmacher, Ramiro Garzon, Clara D. Bloomfield

Blood (2011) 117 (4): 1121–1129.

https://doi.org/10.1182/blood-2010-09-191312

Published: 2011

Journal Articles

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (25): 5660–5669.

https://doi.org/10.1182/blood-2010-06-290536

Published: 2010

Includes: Supplemental data

Journal Articles

Mutations In the Tet Oncogene Family Member 2 ( TET2 ) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Blood (2010) 116 (21): 98.

https://doi.org/10.1182/blood.V116.21.98.98

Published: 2010

Journal Articles

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

Heiko Becker, MD, Kati Maharry, MAS, Michael D. Radmacher, PhD, Dean Margeson, MAS, Krzysztof Mrózek, MD, PhD, Susan P. Whitman, PhD, Yue-Zhong Wu, MS, Klaus H. Metzeler, MD, Sebastian Schwind, MD, Kelsi B. Holland, MS, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Michael A. Caligiuri, MD, Maria R. Baer, MD, Richard A. Larson, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2010) 116 (21): 577.

https://doi.org/10.1182/blood.V116.21.577.577

Published: 2010

Journal Articles

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (18): 3622–3626.

https://doi.org/10.1182/blood-2010-05-283648

Published: 2010

Includes: Supplemental data

Journal Articles

Mutations of the Wilms tumor 1 gene ( WT1 ) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Blood (2010) 116 (5): 788–792.

https://doi.org/10.1182/blood-2010-01-262543

Published: 2010

Includes: Supplemental data

Journal Articles

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Eyal C. Attar, MD, Kati Maharry, MAS, Krzysztof Mrózek, MD, PhD, Michael D. Radmacher, PhD, Susan P. Whitman, PhD, Peter Paschka, MD, Christian Langer, MD, Kelsi B. Holland, MS, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 1616.

https://doi.org/10.1182/blood.V114.22.1616.1616

Published: 2009

Journal Articles

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

Susan P. Whitman, PhD, Kati Maharry, MAS, Michael D. Radmacher, PhD, Krzysztof Mrózek, MD, PhD, Dean Margeson, MAS, Kelsi B. Holland, MS, Heiko Becker, MD, Yue-Zong Wu, MS, Sebastian Schwind, MD, Maria R Baer, MD, Bayard L. Powell, MD, Richard M Stone, MD, Andrew J. Carroll, PhD, Richard A. Larson, MD, Michael A. Caligiuri, MD, Guido Marcucci, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 1579.

https://doi.org/10.1182/blood.V114.22.1579.1579

Published: 2009

Journal Articles

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

Heiko Becker, MD, Guido Marcucci, MD, Kati Maharry, MAS, Michael D. Radmacher, PhD, Krzysztof Mrózek, MD, PhD, Susan P. Whitman, PhD, Peter Paschka, MD, Dean Margeson, MAS, Yue-Zhong Wu, MS, Sebastian Schwind, MD, Christian Langer, MD, Maria R. Baer, MD, Andrew J. Carroll, PhD, Michael A. Caligiuri, MD, Jonathan E. Kolitz, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 326.

https://doi.org/10.1182/blood.V114.22.326.326

Published: 2009

Journal Articles

MODELING and Targeting ERG -INDUCED Acute MYELOID LEUKEMIA (AML).

Gil Smooha, Yehudit Birger, PhD, Liat Goldberg, PhD, Jasmine Jacob-Hirsch, MSc, Ninette Amariglio, PhD, Gideon Rechavi, MD, PhD, Ditsa Levanon, PhD, Yoram Groner, PhD, Anat Taragan, Yoel Kloog, PhD, Jeremy Q Wen, PhD, MD, John Crispino, PhD, Michael D. Radmacher, Guido Marcucci, MD, Clara D. Bloomfield, MD, Shai Izraeli, MD

Blood (2009) 114 (22): 475.

https://doi.org/10.1182/blood.V114.22.475.475

Published: 2009

Journal Articles

Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.

Sebastian Schwind, MD, Guido Marcucci, MD, Kati Maharry, MAS, Krzysztof Mrózek, MD, PhD, Michael D. Radmacher, PhD, Kelsi B. Holland, MS, Heiko Becker, MD, Susan P. Whitman, PhD, Yue-Zhong Wu, MS, Maria R Baer, MD, Bayard L. Powell, MD, Andrew J. Carroll, PhD, Michael A. Caligiuri, MD, Richard A. Larson, MD, Clara D. Bloomfield, MD

Blood (2009) 114 (22): 214.

https://doi.org/10.1182/blood.V114.22.214.214

Published: 2009

Journal Articles

Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC , ERG , and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples.

Jacqueline E. Payton, MD, PhD, Guido Marcucci, M.D., Michael D. Radmacher, Kati Maharry, MAS, Christian Langer, M.D., Claudia D Baldus, Clara D. Bloomfield, M.D., Timothy J. Ley, MD

Blood (2009) 114 (22): 1599.

https://doi.org/10.1182/blood.V114.22.1599.1599

Published: 2009

NARROW

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

MiR-3151 , a Novel MicroRNA Embedded in BAALC , Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

The prognostic and functional role of microRNAs in acute myeloid leukemia

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Mutations In the Tet Oncogene Family Member 2 ( TET2 ) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Mutations of the Wilms tumor 1 gene ( WT1 ) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.

MODELING and Targeting ERG -INDUCED Acute MYELOID LEUKEMIA (AML).

Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study.

Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC , ERG , and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only